Botanical and Plant-derived Drugs: Global Markets
| 出版 | BCC Research |
| 出版年月 | 2025年12月 |
| ページ数 | 135 |
| 価格 | 記載以外のライセンスについてはお問合せください |
| シングルユーザ | USD 4,650.00 |
| 企業ライセンス | USD 8,035.00 |
| 種別 | 英文調査報告書 |
| 商品番号 | SMR-11450 |
Report Highlights
The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.
Report Includes
- 47 data tables and 47 additional tables
- An overview of the global market for botanical and plant-derived drugs
- In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
- Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
- Analysis of drivers, challenges and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
- Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.
Report Scope
The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.
This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2024 | ||||||||||||||||
| Forecast period considered | 2025-2030 | ||||||||||||||||
| Base year market size | $35.8 Billion | ||||||||||||||||
| Market size forecast | $58.1 Billion | ||||||||||||||||
| Growth rate | CAGR of 8.5% for the forecast period of 2025-2030 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Type, Application, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of World | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, China, India, Japan, South Korea, South America, Middle East and Africa | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Table of Contents
Chapter- 1: Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter- 2: Market Overview
Overview
History of Plant-Derived Medicines
Botanical Drugs Value Chain
Macroeconomic Factors Analysis
Porter’s Five Forces Analysis
Chapter- 3: Market Dynamics
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Chapter- 4: Regulatory Landscape
Overview
Chapter- 5: Emerging Technologies and Developments
Key Takeaways
Single-Omics Approaches
Multi-Omics Approaches
Fermentation Technology
Pipeline Analysis
Chapter- 6: Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Product Type
Market Analysis by Application
Geographic Breakdown
Market Analysis by Region
Chapter- 7: Competitive Intelligence
Key Takeaways
Competitive Analysis
Strategic Initiatives
Chapter- 8: Sustainability in the Botanical and Plant-Derived Drugs Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
Concluding Remarks
Chapter- 9: Appendix
Research Methodology
Sources
Acronyms
Company Profiles
Emerging Start-ups/Market Disruptors